

ASX Announcement

Thursday, 25 July 2024

**TGA approval granted for Tissue Repair's TR Pro+™ (AustL 456187, AustL 456188, AustL 456189)**

Tissue Repair is pleased to announce that it has secured a TGA approval for TR Pro+™ the Company's first advanced wound healing gel product containing the proprietary active ingredient, Glucoprime® (0.1%), derived from yeast. The product has been approved in 10g and 50g tubes and 3g sachets (AustL 456187, AustL 456188, AustL 456189).

TR Pro+™ was launched in June 2023 and represents a new standard in the aftercare of medical and aesthetic procedures. The TGA listing will enable the Company to promote its considerable scientific and clinical data more broadly.

Importantly securing general claims around skin healing, repair and regeneration will allow the Company to significantly expand the indications that it can market the product for including acute wounds, and a broad range of derm conditions.

Despite the products current regulatory status as a cosmetic TR Pro+™ sales in June reached a new high with Q3 revenue showing 130% growth over the prior quarter and expanding to over 160 clinics. The short-term focus is on growing distribution.

The Company will shortly provide a broader more detailed update presentation from its co-founder and Executive Director Tony Charara in relation to this significant development and the Company's broader strategies in the immediate commercialisation of its proprietary technology as well as the imminent commencement of Phase 3 clinical trials for its advanced wound drug candidate TR987®.

**About Tissue Repair**

Tissue Repair Limited (ASX TRP) is an advanced biotechnology company developing second generation wound healing agents. The Company is a genuine Phase 3 clinical stage and is planning on shortly commencing its Phase 3 program in chronic wounds for its lead drug candidate TR987®. The Company has a secondary focus on commercialising TR Pro+™ a post procedure topical gel to accelerate healing and improve skin quality post any cosmetic procedure. The Company's longer-term strategy is to commercialize its proprietary Glucoprime® API to treat a variety of wounds and skin conditions.

For further information in relation to this release please contact Darryl Reed at [darryl.reed@trtherapeutics.com](mailto:darryl.reed@trtherapeutics.com) 0419 557 663.

This announcement has been approved for release by TRP's Board.



**Tissue Repair Ltd**

Level 10, 255 Pitt Street, Sydney, NSW 2000

ACN: 158 411 566